

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/173086 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) *A61P 27/02* (2006.01)
A61K 38/22 (2006.01) *A61P 27/06* (2006.01)
A61K 47/68 (2017.01) *C07K 14/58* (2006.01)
A61K 48/00 (2006.01) *C07K 16/22* (2006.01)

(21) International Application Number:

PCT/US2023/064136

(22) International Filing Date:

10 March 2023 (10.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/319,233	11 March 2022 (11.03.2022)	US
63/440,858	24 January 2023 (24.01.2023)	US
63/441,643	27 January 2023 (27.01.2023)	US

(71) Applicant: **AVIRMAX BIOPHARMA INC.** [US/US];
25503 Whitesell Street, Hayward, California 94545 (US).

(72) Inventors: **LIU, Shengjiang**; 25503 Whitesell Street, Hay-
ward, California 94545 (US). **CHEN, Haifeng**; 25503
Whitesell Street, Hayward, California 94545 (US).

(74) Agent: **LIN, Chun Shi**; Wilson Sonsini Goodrich & Rosati,
650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: COMPOSITIONS AND METHODS FOR EXPRESSING THERAPEUTICS

Fig. 1A



(57) Abstract: Described herein are compositions and method for expressing therapeutics. The compositions comprise engineered polypeptides comprising a natriuretic peptide connected to an antibody or fragment thereof. AAV vectors encoding said engineered polypeptides are also disclosed, and therapeutic use thereof to treat diseases such as glaucoma.

WO 2023/173086 A1